Elon Musk's Neuralink has made a groundbreaking advancement in neuroscience by successfully implanting its brain-computer interface in a human patient.
The clinical trial targets individuals suffering from quadriplegia and amyotrophic lateral sclerosis (ALS), aged 22 and above.
A primary objective of the trial is to enable these individuals to control devices using only their thoughts, facilitated by Neuralink's cutting-edge wireless brain-computer interface technology.
This trial is set to offer a new ray of hope for those afflicted with severe movement impairments.
The first human received an implant from @Neuralink yesterday and is recovering well.
Initial results show promising neuron spike detection.
— Elon Musk (@elonmusk) January 29, 2024
Major breakthrough
The successful implantation in a human patient is a major breakthrough for Neuralink, signalling the potential for revolutionary changes in the lives of people with paralysis.
The technology aims to provide a transformative solution for those unable to perform physical movements.
In the previous year, Neuralink received clearance from the Food and Drug Administration (FDA) for human testing of its neural-chip technology.
The recruitment for the trial kicked off in September 2023, specifically focusing on patients suffering from quadriplegia and ALS, over the age of 22.
An independent institutional review board is rigorously overseeing the trial to ensure safety and ethical compliance.